6 considerations in Alzheimer’s Disease drug development
Parexel’s Head of Neurosciences, Andreas Lysandropoulos, outlines six considerations in Alzheimer’s drug development including selecting the right biomarkers in order to meet regulatory needs, pushing boundaries in patient and site recruitment strategy, building a solid value proposition as early as possible. Watch the video to learn more.